Petit M A, Capel F, Gerken G, Dubanchet S, Bréchot C, Trépo C
INSERM U 131, Clamart, France.
Arch Virol Suppl. 1993;8:179-87. doi: 10.1007/978-3-7091-9312-9_18.
These studies assessed whether the serum expression of preS1 antigen could be a useful HBV marker for monitoring the progress of antiviral therapy in the treatment of chronic active hepatitis B (CAH-B) virus infections. Our findings indicate that: 1) the rearrangements we observed in the preS region of mutated HBV DNA molecules during chronic infection did not effect the preS1 sequence (21-47) critical for HBV infectivity; 2) the persistence or even the rebound of preS1 antigen expression during follow-up in responders to antiviral therapy may indicate virus persistence, suggesting the possibility of relapse through wild-type HBV or the emergence of HBV variants following the immunoelimination phase.
这些研究评估了前S1抗原的血清表达是否可作为一种有用的乙肝病毒（HBV）标志物，用于监测慢性活动性乙型肝炎（CAH-B）病毒感染抗病毒治疗的进展情况。我们的研究结果表明：1）我们在慢性感染期间观察到的突变HBV DNA分子前S区域的重排并未影响对HBV感染性至关重要的前S1序列（21-47）；2）抗病毒治疗有反应者在随访期间前S1抗原表达的持续存在甚至反弹可能表明病毒持续存在，提示存在通过野生型HBV复发或免疫清除阶段后出现HBV变异体的可能性。
